Quick Answer
TScan Therapeutics, Inc. reported Diluted EPS of $1.00 per share (loss) for fiscal year 2025.
TScan Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.00 | +12.3% |
| 2024 | -$1.14 | +16.2% |
| 2023 | -$1.36 | +50.5% |
| 2022 | -$2.75 | +34.1% |
| 2021 | -$4.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.28 | -12.0% | +0.0% |
| June 30, 2025 | -$0.28 | +0.0% | -7.7% |
| March 31, 2025 | -$0.26 | +18.8% | -4.0% |
| September 30, 2024 | -$0.25 | -4.2% | +10.7% |
| June 30, 2024 | -$0.28 | +45.1% | +12.5% |
| March 31, 2024 | -$0.32 | +65.6% | -33.3% |
| September 30, 2023 | -$0.24 | +64.2% | +52.9% |
| June 30, 2023 | -$0.51 | +19.0% | +45.2% |
- TScan Therapeutics, Inc. showed an increase of +12.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, TScan Therapeutics, Inc.’s diluted eps has grown by 76.0% (from $4.17 per share (loss) to $1.00 per share (loss)).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: